Glenmark Pharmaceuticals gains on launching Tavulus for COPD treatment in Spain
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Glenmark Pharmaceuticals is currently trading at Rs. 533.00, up by 6.20 points or 1.18 % from its previous closing of Rs. 526.80 on the BSE.
The scrip opened at Rs. 528.25 and has touched a high and low of Rs. 538.40 and Rs. 526.75 respectively. So far 62025 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 690.60 on 19-Jul-2021 and a 52 week low of Rs. 442.15 on 25-Mar-2021.
Last one week high and low of the scrip stood at Rs. 538.40 and Rs. 503.40 respectively. The current market cap of the company is Rs. 15151.02 crore.
The promoters holding in the company stood at 46.63%, while Institutions and Non-Institutions held 36.55% and 16.82% respectively.
Glenmark Pharmaceuticals has launched bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand name ‘Tavulus’ in Spain, for the treatment of chronic obstructive pulmonary disease (COPD).
Tavulus is expected to provide relief to a large patient population in the country. It is a long-acting bronchodilator that helps to open the airways and makes it easier for air to get in and out of the lungs. It also works to prevent sudden, short-term worsening of COPD symptoms.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
